An experimental HIV vaccine used in an international trial may have increased the risk of HIV infection among vaccine recipients,
according to reports in November at a special open meeting of the HIV Vaccine Trials Network in Seattle (http://www.hvtn.org).
The phase 2 trial, which involved 3000 volunteers at high risk for HIV infection, was halted in late September after a preliminary analysis revealed the vaccine had failed to show efficacy.
Stephenson J. HIV Vaccine Concerns? JAMA. 2007;298(23):2733. doi:10.1001/jama.298.23.2733-b
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: